Zimmer Biomet

ZBH

Market cap $19.5B

Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest Speaker WARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting.

WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026.

The S&P 500's annualized total return over the last five years has been roughly 13.5%, but the average stock currently in the index has seen an annualized total return about 2.6 percentage points less at just 10.9%.

Partner Reed Kathrein Scrutinizing ZBH's "High Confidence" Assurances After 15% Stock Collapse and Reduced Revenue Guidance SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company's previously expressed "high confidence" in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit your ZBH losses now.

More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.

Zimmer Biomet Holdings, Inc. (ZBH) Q4 2025 Earnings Call Transcript

Zimmer Biomet beats Q4 earnings and revenue estimates, with sales up 10.9% and shares rising 1.4% pre-market despite margin contraction.

The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.38 per share. This compares to earnings of $2.31 per share a year ago.

Zimmer Biomet on Tuesday beat Wall Street estimates for fourth-quarter profit and revenue as the company capitalized on steady demand for its devices used in orthopedic procedures.